News About: Pharm. Industry
Dongkoo Bio&Pharma to be listed in KOSDAQ market after forecasting demands and subscribingDongkoo Bio&Pharma will go public in the middle of February after forecasting demands between 30 and 31 January and subscribing between 5 and 6 February. The organization of the...
|
Hanmi Pharm’s ‘Olita’ accepted health insurance benefits even with liquid biopsy, soon to be decidedThe range of health insurance benefits for ‘Olita,’ a Hanmi Pharm’s 3rd generation new drug for the treatment of non-small cell lung cancer, is expected to be extended to liquid...
|
KPBMA Chairman Hee-Mok Won resigns due to ‘Government Ethics Act’
Korea Pharmaceutical and Bio-Pharma Manufacturers Association(KPBMA) Chairman Hee-Mok Won resigned his position. It was followed by the Government Ethics Committee’s decision of employment restriction on him.
Previou...
Dong Wha Pharm recruits a person Y from multinational pharma G as new president
Dong Wha Pharm reportedly recruited a president Y from a company G as the new president starting on 1 February.
The person Y has constantly been mentioned as the next president since former President Ji-Hoon Sohn res...
Dong-A ST appoints Korea Otsuka Pharmaceutical CEO Dae-Sik Um as Chairman
As CEO Jang-Sung Man resigned from the position, Dong-A ST decided to appoint Korea Otsuka Pharmaceutical as Dong-A ST Chairman through the Personnel Affairs Committee.
The appointment is the highest position that th...
‘Nabota’ having a rough time before entering U.S., is this a rite of passage?
‘Nabota,’ a botulinum toxin product that Daewoong Pharmaceutical has taken as its future growth engine, had suffered not long ago.
The official document(Form 483) published in the U.S. FDA website about the onsite in...
Will Zemiglo case be accelerated with Sanofi’s submission of marketing data?
The Zemiglo license case which has been postponed by the debate over submission of marketing data might get accelerated.
On the 26th, the Seoul Central District Court Civil Case Division 17 conducted the 8th defense ...
In 2018, a number of Korean pharma medicines expected to acquire approval from U.S. FDA
In 2018, there is a high expectation on the Korean pharmaceutical industry. Along with recent technology exports to other countries, it has been expected there would be a number of products to emerge as a medicine to ...
Ildong Pharmaceutical signs ‘Fambir’ license agreement with Novartis
Ildong Pharmaceutical(CEO Woong-Sup Yoon) announced on the 25th that the company secured the Korean license of ‘Famvir(generic name: famciclovir),’ a Novartis’ viral herpes treatment, and has started to take marketing...
Daewoong Pharmaceutical’s ‘Anplone SR Tab’ wipes the market only in 3 years
Daewoong Pharmaceutical’s ‘Anplone SR Tab’ has become the leading product in the sarpogrelate release-type drug market in 3 years of its launch.
According to Daewoong Pharmaceutical, Anplone SR Tab was ranked the top...
